Anti-inflammatory effect of remifentanil in lipopolysaccharide–stimulated amniotic epithelial cells

Cheul-Hong Kim1, Seong Soon Jeong1, Soon Ji Park2, Eun-Ji Choi2, Yeon Ha Kim3, Ji-Hye Ahn1

1Department of Dental Anesthesia and Pain Medicine, School of Dentistry, Pusan National University, Dental Research Institute, Yangsan, Korea
2Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea
3Department of Integrated Biological Science, Pusan National University, Busan, Korea

Background: Sometimes general anesthesia is required for dental surgery in pregnant women. Facial bone fractures or neck abscess should be treated immediately. Dental surgery, however, creates a stressful situation that can cause inflammation. Inflammatory responses are a well-known major cause of preterm labor and preterm birth. Here we demonstrate the effects of remifentanil on the factors related to preterm labor and its mechanism of action on amniotic-derived epithelial cells (WISH cells).

Methods: WISH cells were exposed to lipopolysaccharide (LPS) for 24 h and co-treated with various concentrations of remifentanil. MTT assays were performed to measure cell viability. To explain the effects of remifentanil on the factors related to inflammation in WISH cells, activation of nuclear factor kappa B (NF-κB) and p38 and the expression of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, cyclooxygenase (COX)2, and prostaglandin E (PGE)2 were quantified using western blotting and RT-PCR, respectively.

Results: Remifentanil did not affect WISH cell viability. In western blot analysis, co-treatment with remifentanil resulted in decreased phosphorylation of NF-κB, and expression of COX2 and PGE2 in LPS-induced inflammation, but the results were statistically significant only at low concentrations. Reduction of IL-1β and TNF-α expression was also observed with RT-PCR.

Conclusion: Co-treatment with remifentanil does not affect the viability of WISH cells, but reduces the expression of the factors related to inflammation, which can induce uterine contraction and preterm labor. These findings provide evidence that remifentanil may inhibit uterine contraction and preterm labor in clinical settings.

Keywords: Amnion; Inflammation; Preterm labor; Remifentanil.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Preterm birth is the most serious problem associated with preterm labor because most babies born preterm (birth that occurs more than three weeks before the estimated due date) are at increased risks of many complications such as neurodevelopmental impairments, respiratory, and gestational complications. Thus, studies on the prevention of preterm labor and preterm birth, and the effect of drugs acting on pregnant women are important fields of study.

Many factors can contribute to preterm labor, such as vaginal bleeding, hormonal changes, stretching of the
uterus (more than 1 baby, a large baby, or too much amniotic fluid) [1]. Additionally, it is well established that inflammation and/or infection represent a significant risk factor in preterm labor [2].

Previous studies have provided clues of how bacterial infections result in inflammation and preterm labor (Fig. 1). The first significant microbiological evidence associated with intrauterine infection before preterm birth was published in the late 1970s, when bacteria were cultured in the amniotic fluid of 7 out of 10 women who had normal membrane, but experienced preterm labor. Bacterial infections can occur within the choriodecidual space, chorion, amnion, placenta, amniotic fluid, within the umbilical cord, or the fetus [3].

Sometimes anesthesia and surgery are required to be performed during pregnancy. Each year, more than 75,000 pregnant women in the United States undergo non-obstetric surgery [4]. The operations include those directly or indirectly related to pregnancy, such as cervical cerclage, ovarian cystectomy, and appendectomy, as well as those unrelated to pregnancy, such as dental surgery. Treatment of accidental fractures or neck abscess with respiratory distress is an operation that cannot be postponed to after childbirth. Surgery can create a stressful situation and elicit an inflammatory response, and anesthetics used for pregnant women during dental surgery might induce preterm labor or birth. Therefore, it is necessary to be sure of the effects of anesthetics meant for use in pregnant patients.

Remifentanil is a synthetic opioid agonist that is used as an anesthesia adjuvant in general anesthesia. Recent studies have shown that remifentanil has anti-inflammatory effects in vitro and in vivo [5,6]. Remifentanil reduces inflammatory cytokine production and exerts a protective effect on lipopolysaccharide (LPS)-induced acute lung injury in rats by down-regulating the nuclear factor kappa B (NF-κB) signaling pathway and acute-phase inflammatory cytokines [7]. Therefore, we aimed to determine whether remifentanil inhibits the expression of crucial mediators of LPS-induced inflammation, such as NF-κB, interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and other factors using human amniotic epithelial cells (WISH cells).
Effect of remifentanil in WISH cells

METHODS

1. Cell culture

An established line of human amnion cells (WISH) was purchased from the American Type Culture Collection (ATCC®, CCL25™, Manassas, VA, USA), and cultured in Eagle’s Minimum Essential Medium (ATCC® 30-2003™, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) in a 5% CO₂ atmosphere at 37°C. Three days later, adherent cells were removed and the culture was continued by replacing the medium twice a week. We have received review exemption approval from the Pusan National University Dental Hospital Institutional Review Board.

2. Remifentanil treatment

This study used a commercially available remifentanil (GlaxoSmithKline, UK). These were diluted with culture medium, and added to cell cultures at various concentrations of remifentanil (0.001 - 1 µg/ml) with Growth medium or LPS (1 µg/ml) for 24 h.

3. MTT assay

WISH cells (1 x 10^5 / well) were seeded on 24-well plates and cultured for 24 h at 37°C in a 5% CO₂ incubator. After that time, cells were exposed to LPS and remifentanil (0.01 - 1 µg/ml) for 24 h. After treatment with remifentanil, the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Affymetrix, Inc. USB, OH, USA] assay was performed by adding 100 µl MTT solution (5 mg/ml in PBS at pH 7.4) into each well, and incubated at 37°C. After 1 h, the medium was removed and 100 µl dimethyl sulfoxide (DMSO; Biosesang) was added into each well. The plate was gently rotated on an orbital shaker for 15 min to completely dissolve the precipitate. The absorbance was detected at 540 nm with a microplate reader (Bio-Rad Model 680). All experiments were repeated three times.

4. Western blot

All cells were extracted with chilled RIPA buffer [50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP40, 5 mM DTT, 0.2 mM Na orthovanadate, 100 mM NaF, 1 mM PMSF] containing protease inhibitor/phosphatase inhibitor cocktail 1X (Cell Signaling Technology, Danvers, MA, USA). Samples (25 µg protein/well) were separated by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to a nitrocellulose (N.C) membrane (Whatman, USA).

The membranes were blocked in TBS-0.1% tween-20 (TBST) containing 3% skim milk for 1 h. The membranes were then incubated with α-tubulin (1:1000; Santa Cruz, CA, USA), nuclear factor kappa B (NF-kB) p65 (1:1000; Santa Cruz), Phospho-NF-kB p65 27.Ser 536 (1:500; Santa Cruz), prostaglandin E (PGE) synthase 2 (A-2) antibody (1:1000; Cell signaling Technology, Danvers, MA, USA), and cyclooxygenase (Cox) 2(D5H5) Rabbit mAb (1:1000; Santa Cruz, CA, USA), and kept overnight at 4°C in TBST with 3% skim milk. After washing three times with TBST, the membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit (1:1000; Enzo Life Sciences), and anti-mouse (1:1000; Santa Cruz) for 1 h at room temperature. Then washing three times with TBST, the bands were visualized by using the ECL detection reagents (Promega, USA). α-Tubulin expression was used as the control. The target protein bands were normalized relative to the control band with an NIH Image program (Image-J launcher).

5. RNA extraction and Reverse transcriptase-polymerase chain reaction (RT-PCR)

Total RNA was extracted from the WISH cells by using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Total mRNA (1 µg) was synthesized to cDNA using oligo (dT) PrimeScript™ 1st strand cDNA Synthesis Kits (TaKaRa Clontech, BD Biosciences, Palo Alto, CA, USA) according to the manufacturer’s instructions. RT-PCR was done on a SimpliAmp Thermal Cycler.
Cheul-Hong Kim, et al

(Applied Biosystems, LifeScience Technologies, CA, USA). Polymerase chain reaction (PCR) primers were as follows: interleukin (IL)-1β, Forward: 5′-CTG GGC AGT GAA ATG ATG GCT-3′, Reverse: 5′-TGC GGA GAT TCG TAG CTG GAT-3′; tumor necrosis factor (TNF)-α, Forward: 5′-CCA GGC AGT CAG ATC ATC TTC-3′, Reverse: 5′-GTC GGA GAT TCG TAG CTG GAT-3′; β-actin, Forward: 5′-GAC CTG ACT GAC TAC CTC ATG-3′, Reverse: 5′-CGC TCA TTG CCA ATG GTG ATG-3′. Amplification of IL-1β/β-actin was performed using 35 cycles of 95℃ for 30 s, 55℃ for 30 s, and 72℃ for 30 s with a final extension of product at 72℃ for 7 min. Amplification of TNF-α/β-actin was performed using 35 cycles of 94℃ for 30 s, 54℃ for 30 s, and 72℃ for 30 s with a final extension of product at 72℃ for 10 min. PCR-amplified products were separated on 1.5% stained agarose gels. The Gel Doc ImageQuant LAS 500 System (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was used to assay the PCR products. β-Actin was used to normalize all target genes. The data were analyzed using INH Image program (Image-J Launcher).

6. Enzyme-Linked immunosorbent assay (ELISA)

WISH cells were seeded at a density of 1 x 10⁶ cells/ml in a 6-well plate, and incubated with remifentanil (0.001, 0.01, 0.1 and 1 µg/ml) in the presence of LPS (1 µg/ml) for 24 h following the manufacturer’s instructions. Supernatants were harvested and levels of PGE₂ and COX-2 were measured using a commercially available ELISA kit (product numbers ADI-900-001, ADI-900-094 respectively, all Enzo Life Sciences, Inc, USA).

The results were normalized to LPS, and presented as concentration in PGE₂ and COX-2 levels of at least three independent experiments.

7. Statistics

The data values represent the means ± standard deviation of the mean. Statistical significance was determined using the SigmaPlot v10 software. A P value < 0.05 was considered statistically significant.

RESULTS

1. Effects of remifentanil and LPS on cell viability in WISH cells

MTT assays were used to evaluate the effects of remifentanil and/or LPS on WISH cells. WISH cells were incubated with remifentanil (0.001-1 µg/ml) and/or LPS (1 µg/ml) for 24 h. Data are presented as mean ± SD. All experimental results were repeated three times.

Fig. 2. In MTT assay, LPS and remifentanil did not affect the viability of WISH cells. WISH cells were incubated with remifentanil (0.001-1 µg/ml) and/or LPS (1 µg/ml) for 24 h. Data are presented as mean ± SD. All experimental results were repeated three times.

2. Remifentanil regulated the phosphorylation of NF-κB and p38 in LPS-stimulated WISH cells

Western blot analysis was performed to investigate the activation of NF-κB and p38. According to a previous study, phosphorylation of NF-κB and p38 activates the inflammatory pathway [8]. Western blot analysis suggested that LPS significantly increased NF-κB and p38 phosphorylation, and phosphor-NF-κB and phosphor-p38 levels decreased in the remifentanil co-treatment WISH cells (Fig. 3).

3. Remifentanil reduced the expression of pro-inflammatory cytokines (IL-1β and TNF-α) in LPS-stimulated WISH cells

RT-PCR was performed to quantify the expression of
Effect of remifentanil in WISH cells

**Fig. 3.** Remifentanil inhibited phosphorylation of NF-κB and p38 (activated form of NF-κB and p38) in LPS-stimulated WISH cells using western blot analysis. 

*##P < 0.01, ###P < 0.001 versus control group; *P < 0.05, **P < 0.01, ***P < 0.001 versus LPS group.*

**Fig. 4.** RT-PCR analysis showed that co-treatment with remifentanil reduced the amount of mRNA expression of pro-inflammatory cytokines, such as IL-1β and TNF-α in the WISH cells at a very low concentration.

*#P < 0.05, ###P < 0.001 versus control group; *P < 0.05 versus LPS group.*

the pro-inflammatory cytokines (IL-1β and TNF-α) induced by inflammation. The analysis detected that co-treatment with remifentanil reduced mRNA expression of IL-1β and TNF-α in the cells at a very low concentration (0.001 μg) (Fig. 4).
Fig. 5. Remifentanil co-treatment decreased COX-2 and PGE₂ production in LPS-stimulated WISH cells. It was measured using ELISA. 

\[ #P < 0.05, \ ##P < 0.01 \text{ versus control group; } ^*P < 0.05 \text{ versus LPS group.} \]

4. Remifentanil decreased COX₂ and PGE₂ production in LPS-stimulated WISH cells

LPS induced cell inflammation and increased PGE₂ and COX-2 levels in WISH cells. Co-treatment with remifentanil reduced PGE₂ and COX-2 production after inducing inflammation with LPS in the WISH cells. It was measured using ELISA (Fig. 5).

DISCUSSION

We tested the hypothesis that premature labor may occur due to inflammatory response and that remifentanil might decrease the inflammation by downregulating various factors involved in inflammatory response, thereby protecting against early uterine contraction.

Co-treatment with remifentanil at the tested concentrations and LPS was not toxic to the WISH cells. According to previous reports, 0.5–12 ng/ml and 6–9 ng/ml blood concentrations of remifentanil were used to maintain general anesthesia for long-term use in intensive care unit sedation [9,10]. Thus, the remifentanil at a low concentrations (0.001, 0.01 μg/ml) in our study design are appropriate for clinical use.

LPS is the most common element within the cell wall of Gram-negative bacteria. Inflammatory cytokines are released due to its stimulation in various cell types, which provokes an inflammatory response to pathogens [11].

Toll-like receptors (TLRs) are transmembrane pattern recognition receptors (PRRs), which combine with patterns of molecular structures present on the surfaces of microorganisms. TLR-4 recognizes LPS [12,13].

Stimulation of TLRs modulates the activation of NF-κB, which leads to the production of antimicrobial peptides, cytokines, and chemokines [12]. NF-κB consists of five subunits, of which the p65 (also named RelA) and p50 subunits play a central role in NF-κB activation [14]. Phosphorylation of NF-κB occurs via two different signaling pathways, the non-canonical and canonical pathways. The canonical NF-κB pathway relies on inducible degradation of IκBα by phosphorylation, which leads to the nuclear translocation of NF-κB complexes, mainly the p50/RelA dimer [15]. From our study, co-treatment with remifentanil decreased the level of NF-κB and p38 phosphorylation at 0.001 and 0.01 μg/ml, respectively. Therefore, we can speculate that remifentanil inhibits the inflammatory response through the canonical pathway in WISH cells.

Accumulated evidence suggest that cytokines such as IL-6, IL-1β, and TNF-α play a central role in the mechanisms of infection/inflammation-induced preterm labor. IL-1 is the first cytokine involved in the onset of spontaneous preterm labor related to inflammation [16–18]. IL-1 stimulates prostaglandin expression, and can stimulate myometrial contractions [19,20]. TNF-α also increases the level of prostaglandin production by the amnion, decidua, and myometrium, and the
concentration of TNF-α is elevated in women with preterm labor [21]. Our data demonstrate that remifentanil significantly decreased the expression of IL-1β, TNF-α, COX-2, and PGE2.

These results suggest that remifentanil may exert a cell protective effect against microbial-induced inflammatory response through the inhibition of NF-κB activation. Although this study had some limitations, we used a range of drugs that could be applied clinically, and within this drug range, we predicted that the inhibitory effect on inflammatory factors would increase with increasing drug concentrations. Remifentanil inhibited NF-κB at low concentrations and could not effectively inhibit NF-κB at concentrations higher than 0.01 μg/ml. Therefore, further research is needed to determine whether at high concentrations, remifentanil is involved in other inflammatory pathways.

ACKNOWLEDGEMENTS: This work was supported by a 2-Year Research Grant from Pusan National University.

NOTE: There are no financial or other issues that might lead to conflict of interest.

REFERENCES

16. Romero R, Brody DT, Oyarzun E, Mazor M, Wu YK,


